283 related articles for article (PubMed ID: 22575166)
1. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2012 Jun; 30(31):4655-60. PubMed ID: 22575166
[TBL] [Abstract][Full Text] [Related]
2. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial.
Pleguezuelos O; Dille J; de Groen S; Oftung F; Niesters HGM; Islam MA; Næss LM; Hungnes O; Aldarij N; Idema DL; Perez AF; James E; Frijlink HW; Stoloff G; Groeneveld P; Hak E
Ann Intern Med; 2020 Apr; 172(7):453-462. PubMed ID: 32150750
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
6. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.
Taylor DN; Treanor JJ; Sheldon EA; Johnson C; Umlauf S; Song L; Kavita U; Liu G; Tussey L; Ozer K; Hofstaetter T; Shaw A
Vaccine; 2012 Aug; 30(39):5761-9. PubMed ID: 22796139
[TBL] [Abstract][Full Text] [Related]
7. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
[TBL] [Abstract][Full Text] [Related]
9. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
10. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
12. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
16. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
Falsey AR; Treanor JJ; Tornieporth N; Capellan J; Gorse GJ
J Infect Dis; 2009 Jul; 200(2):172-80. PubMed ID: 19508159
[TBL] [Abstract][Full Text] [Related]
18. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.
Francis JN; Bunce CJ; Horlock C; Watson JM; Warrington SJ; Georges B; Brown CB
Vaccine; 2015 Jan; 33(2):396-402. PubMed ID: 24928790
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
